Last reviewed · How we verify

NCT07319208: COSMOS-TBI

Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients.

Recruiting now Phase 3 Last updated 6 April 2026
What this trial tests

Phase 3 trial testing Hypertonic saline solution in TBI Traumatic Brain Injury in 760 participants. Currently enrolling.

Timeline
1 May 2026
Primary endpoint
1 June 2028
1 June 2029

Quick facts

Lead sponsorNantes University Hospital
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment760
Start date1 May 2026
Primary completion1 June 2028
Estimated completion1 June 2029
Sites23 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 75, any sex, with TBI Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the efficacy of early continuous intravenous infusion of hypertonic saline solution (HSS) to improve survival and independence in daily life activities (at 6 months) of patients with traumatic brain injury at high risk of intracranial hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hypertonic saline solution

Trials testing the same drug.

Other recruiting trials for TBI Traumatic Brain Injury

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07319208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing